Cullinan Therapeutics (CGEM) Capital Expenditures (2020 - 2025)
Cullinan Therapeutics (CGEM) posted quarterly Capital Expenditures of $11000.0 for Q4 2025, down 77.55% quarter-over-quarter from $49000.0 in Q2 2023.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) Capital Expenditures (2020 - 2025) Analysis & Trends
Cullinan Therapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at $11000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures changed N/A year-over-year to $11000.0; the TTM figure through Dec 2025 stood at $11000.0 (changed N/A YoY), while the FY2025 annual figure was $49000.0, changed N/A from the prior year.
- Capital Expenditures for Q4 2025 stood at $11000.0, down from $49000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $882000.0 in Q4 2022, with the low at $11000.0 in Q4 2025.
- The 3-year median for Capital Expenditures is $159000.0 (2023), against an average of $270400.0.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 11,000.00 |
| Jun 30, 2023 | 49,000.00 |
| Mar 31, 2023 | 159,000.00 |
| Dec 31, 2022 | 882,000.00 |
| Sep 30, 2022 | 251,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 4,000.00 |
| Jun 30, 2020 | 4,000.00 |
| Mar 31, 2020 | 3,000.00 |